EPHA2 and breast cancer: Huang et al. measured EPHA2 expression levels after dasatinib application in sensitive BC cell lines by quantitative real-time PCR (qRT-PCR), and reported a significant, partly Src-dependent, reduction in EPHA2 expression, phosphorylation, and kinase activity upon dasatinib treatment [23].